Previous studies [78,79] have highlighted the involvement of other RTKs in the response to EGFR inhibitors in cancer, including human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and MET (also known as hepatocyte growth factor receptor or HGFR). This evidence concerns the gene ERBB3 and cancer.